Cadrenal Therapeutics, Inc. ( (CVKD) ) has released its Q2 earnings. Here is a breakdown of the information Cadrenal Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative anticoagulation therapies, with its lead product being tecarfarin, aimed at addressing the limitations of current treatments. In its latest earnings report for the second quarter of 2025, Cadrenal Therapeutics highlighted its strategic focus on advancing tecarfarin into clinical trials for patients with end-stage kidney disease transitioning to dialysis. The company has made significant progress in its clinical and manufacturing readiness, including the successful technical transfer and production of tecarfarin at a U.S. site. Financially, the company reported a net loss of $3.7 million for the quarter, with research and development expenses slightly decreasing compared to the previous year, while general and administrative expenses saw an increase. Looking ahead, Cadrenal remains committed to expanding its clinical pipeline and exploring strategic collaborations to enhance its position in the anticoagulation therapy market.